Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AMP 886

Drug Profile

AMP 886

Alternative Names: AMP-886; CTx-0294886; CTx-294886; CTx294886;

Latest Information Update: 18 Dec 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cancer Therapeutics CRC; Cytopia Research
  • Developer Amplia Therapeutics Limited
  • Class Antineoplastics; Hepatoprotectants; Small molecules
  • Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Focal adhesion protein-tyrosine kinase inhibitors; Vascular endothelial growth factor receptor 3 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Preclinical Acute myeloid leukaemia; Non-alcoholic steatohepatitis

Most Recent Events

  • 01 Dec 2022 AMP 886 is available for licensing as of 01 Dec 2022. https://www.ampliatx.com/site/content/ (Amplia Therapeutics pipeline, December 2022)
  • 01 Dec 2022 Preclinical trials in Acute myeloid leukaemia in Australia (PO) prior to December 2022 (Amplia Therapeutics pipeline, December 2022)
  • 01 Dec 2022 Preclinical trials in Non-alcoholic steatohepatitis in Australia (unspecified route) prior to December 2022 (Amplia Therapeutics pipeline, December 2022)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top